Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001442 · ClinicalTrials.gov registry record · Phase 1

A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer

A Phase 1 study of Squamous Cell Carcinoma and Head and Neck Neoplasm, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 1
Development phase
35
Enrollment target
1
Study location

NCT00001442 is a Phase 1 study of Squamous Cell Carcinoma and Head and Neck Neoplasm that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001442, a Phase 1 study of Squamous Cell Carcinoma and Head and Neck Neoplasm, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 1
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

Radiotherapy plus Single-Agent Chemotherapy/Radiosensitization. Irradiation of tumor and involved nodes using 4-6 MV photons (brachytherapy allowed to boost primary tumor; electrons allowed to boost posterior neck and massive adenopathy); plus Paclitaxel (Bristol-Myers), Taxol, TAX, NSC-125973.

Interventions

  • DRUG paclitaxel concurrent with radiation therapy

Study Locations (1)

Maryland

  • National Cancer Institute (NCI) - Bethesda

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 1995-07
Est. Completion 2004-06
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00001442

The ClinicalTrials.gov registry entry for NCT00001442 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (66% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which paclitaxel concurrent with radiation therapy is the first listed.

NCT00001442 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00001442 about?

NCT00001442 is a clinical study titled "A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer". Radiotherapy plus Single-Agent Chemotherapy/Radiosensitization. Irradiation of tumor and involved nodes using 4-6 MV photons (brachytherapy allowed to boost primary tumor; electrons allowed to boost posterior neck and massive adenopathy); plus Paclitaxel (Bristol-Myers), Taxol, TAX, NSC-125973.

What is the current status of trial NCT00001442?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 1995-07. Estimated completion is 2004-06.

What conditions does trial NCT00001442 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma, Head and Neck Neoplasm.

What interventions are being tested in trial NCT00001442?

The interventions under investigation include: paclitaxel concurrent with radiation therapy (DRUG).

Who is sponsoring clinical trial NCT00001442?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00001442 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Squamous Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.